(Q35821602)

10 August 2017

1 reference

title

Proteasome inhibition in hematologic malignancies (English)

1 reference

10 August 2017

1

Paul G Richardson

1 reference

10 August 2017

4

Kenneth Anderson

1 reference

10 August 2017

2

Teru Hideshima

1 reference

10 August 2017

Constantine S Mitsiades

series ordinal

3

object named as

Constantine Mitsiades

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

36

1 reference

10 August 2017

issue

4

1 reference

10 August 2017

page(s)

304-314

1 reference

10 August 2017

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1080%2F07853890410030877

Current therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890410030877

Proteasome inhibition in cancer: development of PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890410030877

Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890410030877

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890410030877

Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890410030877

The proteasome: a new target for novel drug therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890410030877

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890410030877

The proteasome: a novel target for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890410030877

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890410030877

Targeted therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890410030877

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890410030877

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890410030877

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890410030877

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890410030877

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890410030877

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890410030877

10.1080/07853890410030877

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference